MAM
CBMG

Meeder Asset Management’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Meeder Asset Management’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-766
Closed -$12K – 2671
2020
Q1 		$12K Sell
766
-2,429
-76% -$39.3K ﹤0.01% 1456
2019
Q4 		$52K Buy
3,195
+2,842
+805% +$47.4K ﹤0.01% 1010
2019
Q3 		$5K Hold
353
– – ﹤0.01% 1793
2019
Q2 		$6K Sell
353
-2,876
-89% -$47K ﹤0.01% 1641
2019
Q1 		$57K Sell
3,229
-217
-6% -$3.94K ﹤0.01% 846
2018
Q4 		$61K Buy
3,446
+3,188
+1,236% +$54.1K 0.01% 762
2018
Q3 		$4K Buy
+258
New +$5.29K ﹤0.01% 1380
2018
Q2 		– Sell
-53
Closed -$1K – 1736
2018
Q1 		$1K Sell
53
-496
-90% -$9.08K ﹤0.01% 1510
2017
Q4 		$6K Buy
549
+66
+14% +$689 ﹤0.01% 1290
2017
Q3 		$5K Sell
483
-62
-11% -$587 ﹤0.01% 1298
2017
Q2 		$5K Sell
545
-74
-12% -$652 ﹤0.01% 1224
2017
Q1 		$7K Buy
619
+265
+75% +$3.22K ﹤0.01% 977
2016
Q4 		$5K Buy
+354
New +$4.74K ﹤0.01% 867

Other funds holding CBMG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Meeder Asset Management's CBMG Position: Q2 2020 in Review

Meeder Asset Management sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q2 2020, closing a stake of 766 shares — an estimated $12K sold.

Meeder Asset Management first reported a position in CBMG in Q4 2016 and held it in 13 quarters. The position peaked at $61K in Q4 2018. 45 funds tracked by Wall St. Rank hold CBMG as of Q2 2020.

  • Meeder Asset Management reported no remaining Cellular Biomedicine Group, Inc. position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 766 Cellular Biomedicine Group, Inc. shares in Q2 2020, an estimated $12K.
  • Meeder Asset Management first reported a position in Cellular Biomedicine Group, Inc. in Q4 2016 and held it in 13 quarters.
  • Meeder Asset Management's Cellular Biomedicine Group, Inc. position peaked at $61K in Q4 2018.
  • 45 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.